#Anaheim_Bio
Anaheim Bio Secures 40 Million Euros to Advance Innovative ANA-1 Treatment into Clinical Trials#Netherlands#Leiden#Anaheim_Bio#ANA-1#CPPD
Anaheim Bio Secures 40 Million Euros to Advance Innovative ANA-1 Treatment into Clinical Trials
Anaheim Bio has raised 40 million euros in Series A funding to further develop ANA-1, a promising treatment for calcium pyrophosphate deposition disease, entering clinical trials soon.
third-news.com
November 9, 2026 at 3:50 PM
Anaheim Bio Secures €40 Million to Develop Innovative Treatment for CPPD#USA#Leiden#Anaheim_Bio#ANA-1#CPPD
Anaheim Bio Secures €40 Million to Develop Innovative Treatment for CPPD
Anaheim Bio, a new biotechnology firm, has raised €40 million in Series A funding to advance ANA-1, a therapeutic for treating calcified joint diseases.
third-news.com
November 5, 2026 at 12:28 PM
Anaheim Bio Secures €40 Million Series A Financing to Combat Calcium Pyrophosphate Deposition Disease#Netherlands#Leiden#Anaheim_Bio#ANA-1#CPPD
Anaheim Bio Secures €40 Million Series A Financing to Combat Calcium Pyrophosphate Deposition Disease
Anaheim Bio, a biotech firm, has announced its launch with €40 million in Series A funding aimed at advancing its treatment for CPPD. The compound, ANA-1, is set to enter clinical trials in 2027.
third-news.com
November 5, 2026 at 12:26 PM